A Phase I, Single Group Treatment, Open-Label, Two-Stage Study to Investigate the Effect of Repeat Doses of Fluvoxamine (A Strong CYP1A2 Inhibitor) and Paroxetine (A Strong CYP2D6 Inhibitor) and Smoking on the Pharmacokinetics of Single-Dose IPN60170 in Healthy Male Participants - Global

A Phase I, Single Group Treatment, Open-Label, Two-Stage Study to Investigate the Effect of Repeat Doses of Fluvoxamine (A Strong CYP1A2 Inhibitor) and Paroxetine (A Strong CYP2D6 Inhibitor) and Smoking on the Pharmacokinetics of Single-Dose IPN60170 in Healthy Male Participants

Back

A Phase I, Single Group Treatment, Open-Label, Two-Stage Study to Investigate the Effect of Repeat Doses of Fluvoxamine (A Strong CYP1A2 Inhibitor) and Paroxetine (A Strong CYP2D6 Inhibitor) and Smoking on the Pharmacokinetics of Single-Dose IPN60170 in Healthy Male Participants

- 20 November 2023 - 1 mins read
A Phase I, Single Group Treatment, Open-Label, Two-Stage Study to Investigate the Effect of Repeat Doses of Fluvoxamine (A Strong CYP1A2 Inhibitor) and Paroxetine (A Strong CYP2D6 Inhibitor) and Smoking on the Pharmacokinetics of Single-Dose IPN60170 in Healthy Male Participants

IPN60170

Related Documents